Home › Compare › IBJHF vs ABBV
IBJHF yields 3.15% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, IBJHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IBJHF + ABBV for your $10,000?
Ibstock plc manufactures and sells clay and concrete building products and solutions primarily in the United Kingdom. Its principal products include clay bricks, brick components, concrete roof tiles, concrete stone masonry substitutes, concrete fencing, pre-stressed concrete, and concrete rail products. The company provides facing bricks, special bricks, walling stones, architectural masonry products, facade systems, retaining walls, sills and arches, and padstones, as well as lintels, sills, and arches; cladding solutions; roof tiles, roof window systems, chimneys, soffits, and roofing accessories; and fencings, caps and copings, bollards, balustrades, path edgings, and urban landscaping products. It also offers floor beams, door steps, gully surrounds, screed rails, insulated floorings, and hollowcore products; and rail and infrastructure products, such as troughing, cable theft protection, boards, blocks, bases, catchpits, and inspection chambers. In addition, the company offers engraving, cutting, and bonding services; floor beam and block design, supply, and fitting solutions; bespoke concrete products; and staircases and lift shafts services. Its products are used in new build housing; repair, maintenance, and improvement; and infrastructure markets. The company sells its products under the Forticrete, Supreme, Anderton, and Longley brands to customers in the construction industry. Ibstock plc was founded in 1825 and is headquartered in Ibstock, the United Kingdom.
Full IBJHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.